| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1955-09-29 |
| Identifiers | MRN HR-ML032-SYN-TD; SSN (made up) 000-32-5814 |
| Document date | 2016-02-24 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review three weeks after surgical staging, on the first treatment day. [S]
Ms. Ifill returns three weeks after robotic-assisted hysterectomy with removal of both tubes and ovaries, sentinel node mapping and removal of the enlarged para-aortic node. She went home the next morning, needed acetaminophen for about a week and nothing since, and has had no bleeding, fever, leg swelling or bladder trouble. She went back to work last week. The final pathology and molecular results are back, and the multidisciplinary tumor board reviewed them with Dr. Delacroix. She saw the genetic counselor this morning. She came today for her first cycle of dostarlimab with carboplatin and paclitaxel. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Operation | Minimally invasive; home the next day; port sites healed |
| Pathology | Endometrioid adenocarcinoma, grade 2, 65% myometrial invasion; right pelvic sentinel node and one para-aortic node involved |
| Stage and molecular class | FIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type |
| Lynch syndrome screen | MLH1 promoter hypermethylated: acquired, not inherited |
| Today | Cycle 1 of dostarlimab, carboplatin and paclitaxel |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight 72.6 kg |
| Genitourinary | Negative | No vaginal bleeding or discharge; no urinary symptoms |
| Gastrointestinal | Negative | No nausea, diarrhea or abdominal pain |
| Neurological | Negative | No tingling or numbness in the hands or feet |
| Cardiovascular | Negative | No calf pain or leg swelling |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood steady; PHQ-9 5; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2016-02-03 to 2016-02-17 | completed | S |
| Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2016-02-24 to 2016-06-30 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2016-02-24 | Body height | 165 | cm | S |
| 2016-02-24 | Body weight | 72.6 | kg | S |
| 2016-02-24 | Body mass index (BMI) [Ratio] | 26.7 | kg/m2 | S |
| 2016-02-24 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2016-02-24 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2016-02-24 | Heart rate | 80 | /min | S |
| 2016-02-24 | Respiratory rate | 16 | /min | S |
| 2016-02-24 | Body temperature | 36.7 | Cel | S |
| 2016-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2016-02-24 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2016-02-24 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2016-02-24 | Neutrophils [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2016-02-24 | Platelets [#/volume] in Blood by Automated count | 301 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2016-02-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2016-02-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2016-02-24 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2016-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2016-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 2016-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2016-02-24 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2016-02-24 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2016-02-24 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2016-02-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2016-02-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2016-02-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 80; weight 72.6 kg |
| Abdomen | Port-site incisions healed without redness or hernia; soft, non-tender |
| Extremities | No leg or genital swelling; calf circumferences equal (baseline for lymphedema) |
| Neurological | Light touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel) |
| Skin | No rash (baseline before a checkpoint inhibitor) |
| Psychiatric | Focused and well informed; asks detailed questions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
| Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2013 stage IIIC2ii | active | confirmed | C77.8 | S — Synthetic nodal disease found at surgical staging. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology, stage and molecular class | After surgery | Up to date | FIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type; estrogen receptor positive |
| Laboratory | MLH1 promoter methylation | Reflex when MLH1 is lost | Up to date | Hypermethylated: the mismatch repair loss is acquired in the tumor |
| Referral | Genetic counseling | When the tumor screen is abnormal | Completed today | Seen this morning; the result was explained |
| Laboratory | Germline testing for Lynch syndrome and cascade testing of relatives | If MMR loss is not explained by MLH1 methylation, or with a strong family history | Not indicated | MLH1 loss is explained by promoter methylation; she knows that a new family history of colorectal or endometrial cancer at a young age would be a reason to revisit this |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Up to date | All negative; no antiviral prophylaxis needed |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 11.6 g/dL, white cells 6.4, neutrophils 3.9, platelets 301 |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.78 mg/dL, eGFR 87; carboplatin 575 mg for AUC 5 |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 18, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 4.0 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 2.0 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 1.9 mIU/L, free T4 1.2 ng/dL (baseline) |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 92 mg/dL (baseline) |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Deferred | Not drawn: she arrived after the morning window, when a cortisol cannot be read. To be drawn before 9 a.m. before cycle 2 in the infusion center. No symptom of adrenal insufficiency |
| Examination | Peripheral neuropathy: symptoms and examination | Baseline and before each taxane cycle | Completed today | Baseline normal before the first paclitaxel dose |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling; baseline calf measurements recorded |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Three-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | Dexamethasone, diphenhydramine and famotidine before the infusion; observation in the first hour |
| Medication safety | Immune-related adverse event teaching | Before the first checkpoint inhibitor dose and each visit | Completed today | Wallet card and written list of symptoms to report the same day |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 5; no thoughts of self-harm |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); Eskander RN, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NRG-GY018). N Engl J Med 2023;388(23):2159-2170 (PMID 36972022) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Cycles every 21 days in the infusion center, with blood counts, chemistry, TSH and a morning cortisol before cycle 2. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more, diarrhea, rash, cough or breathlessness. Next scheduled visit 2016-04-28: midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood. [S]